CORDIS
EU research results

CORDIS

English EN

Development of Vaccines for bTV, EHDV and AHSV

Project information

Grant agreement ID: 245266

Status

Closed project

  • Start date

    1 February 2010

  • End date

    31 January 2014

Funded under:

FP7-KBBE

  • Overall budget:

    € 4 152 050,20

  • EU contribution

    € 2 999 729

Coordinated by:

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom

Objective

The major outstanding challenges of orbivirus vaccine research is to develop vaccines that can afford a broad protective immune response against as many serotypes of each virus as possible, and to develop a high throughput DIVA assay (e.g. an ELISA). This project will use a coordinated multipartner approach to address these issues, to develop new experimental prototype vaccines and diagnostic approaches. It will build on specific expertise and reagents that are only available within the consortium and will link out to other international efforts in USA and South Africa to develop improved vaccines for these diseases. The consortium includes a number of industrial partners who are already active in vaccine manufacture for these and other veterinary diseases, in order to ensure that the findings of the research are transferred as soon as possible into commercial vaccines for European livestock. The project also includes two SMEs, who will be specifically involved in the development of DIVA compatible diagnostic tests. In summary, the specific objectives of the project will be: to develop multivalent vaccines using different approaches for Orbiviruses responsible for livestock diseases, in particular, Bluetongue Virus (BTV), African Horse Sickness Virus (AHSV) and Epizootic Haemorrhagic Disease Virus (EHDV); to understand the best vaccination strategy to elicit multi-serotype protection for these viruses in livestock and analyze immune responses for each of the novel vaccines developed for breadth of protection against multiple serotypes; and to develop DIVA compatible diagnostics that will work with the new vaccines developed in order to differentiate between vaccinated and infected animals.

Coordinator

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

Address

Keppel Street
Wc1e 7ht London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 743 127

Administrative Contact

Greg Dow (Mr.)

Participants (17)

AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU TRAVAIL

France

EU Contribution

€ 329 250

UNIVERSIDAD COMPLUTENSE DE MADRID

Spain

EU Contribution

€ 261 306

CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LEDEVELOPPEMENT - C.I.R.A.D. EPIC

France

EU Contribution

€ 180 000

MERIAL SAS

France

EU Contribution

€ 33 358

ZOETIS MANUFACTURING & RESEARCH SPAIN SL

Spain

EU Contribution

€ 168 020

INTERVET INTERNATIONAL BV

Netherlands

BOEHRINGER INGELHEIM VETMEDICA GMBH

Germany

EU Contribution

€ 5 000

FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT

Germany

EU Contribution

€ 350 000

STICHTING WAGENINGEN RESEARCH

Netherlands

EU Contribution

€ 307 500

DELTAMUNE (PTY) LTD

South Africa

EU Contribution

€ 60 000

KANSAS STATE UNIVERSITY

United States

EU Contribution

€ 6 000

THE PIRBRIGHT INSTITUTE LBG

United Kingdom

EU Contribution

€ 287 168

CENTRUM VOOR ONDERZOEK IN DIERGENEESKUNDE EN AGROCHEMIE - CODA

Belgium

EU Contribution

€ 200 000

ID VET

France

EU Contribution

€ 60 000

INMUNOLOGIA Y GENETICA APLICADA SA

Spain

EU Contribution

€ 9 000

AGENCE FRANCAISE DE SECURITE SANITAIRE DES ALIMENTS

France

FORT DODGE VETERINARIA, S.A.

Spain

Project information

Grant agreement ID: 245266

Status

Closed project

  • Start date

    1 February 2010

  • End date

    31 January 2014

Funded under:

FP7-KBBE

  • Overall budget:

    € 4 152 050,20

  • EU contribution

    € 2 999 729

Coordinated by:

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom